Compounds > przewaquinone d
Page last updated: 2024-12-07

przewaquinone d

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

przewaquinone D: isolated from root of Salvia przewalskii; structure given in first source; RN given refers to the trans- isomer, przewaquinone D [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
SalviagenusA genus in the mint family (LAMIACEAE).[MeSH]LamiaceaeThe mint plant family. They are characteristically aromatic, and many of them are cultivated for their oils. Most have square stems, opposite leaves, and two-lipped, open-mouthed, tubular corollas (united petals), with five-lobed, bell-like calyxes (united sepals).[MeSH]

Cross-References

ID SourceID
PubMed CID126072
CHEMBL ID3287734
SCHEMBL ID14417695
MeSH IDM0127160

Synonyms (17)

Synonym
przewaquinone d
(6r,7r)-6,7-dihydroxy-1,6-dimethyl-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione
96839-30-4
chembl3287734 ,
bdbm50017292
przewaquinone e
phenanthro(1,2-b)furan-10,11-dione, 6,7,8,9-tetrahydro-6,7-dihydroxy-1,6-dimethyl-
SCHEMBL14417695
tanshindiol c
97465-71-9
6,7-dihydroxy-1,6-dimethyl-6,7,8,9-tetrahydrophenanthro[1,2-b]furan-10,11-dione
DTXSID30914287
MS-24549
phenanthro[1,2-b]furan-10,11-dione, 6,7,8,9-tetrahydro-6,7-dihydroxy-1,6-dimethyl-, (6r,7r)-(-)-
HY-122936
CS-0090502
AKOS040762395
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (5)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Polycomb protein EEDHomo sapiens (human)IC50 (µMol)0.55000.00201.21958.9000AID1151968
Polycomb protein EEDHomo sapiens (human)Ki0.19400.00120.09760.1940AID1151969
Histone-binding protein RBBP4Homo sapiens (human)Ki0.19400.00120.09760.1940AID1151969
Polycomb protein SUZ12Homo sapiens (human)IC50 (µMol)0.55000.00401.61908.9000AID1151968
Polycomb protein SUZ12Homo sapiens (human)Ki0.19400.00120.09760.1940AID1151969
Histone-lysine N-methyltransferase EZH2Homo sapiens (human)IC50 (µMol)0.55000.00030.50478.9000AID1151968; AID1882367
Histone-lysine N-methyltransferase EZH2Homo sapiens (human)Ki0.19400.00050.03170.1940AID1151969; AID1882373
Histone-binding protein RBBP7Homo sapiens (human)Ki0.19400.00120.09760.1940AID1151969
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (68)

Processvia Protein(s)Taxonomy
spinal cord developmentPolycomb protein EEDHomo sapiens (human)
negative regulation of DNA-templated transcriptionPolycomb protein EEDHomo sapiens (human)
heterochromatin formationPolycomb protein EEDHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIPolycomb protein EEDHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone-binding protein RBBP4Homo sapiens (human)
DNA replicationHistone-binding protein RBBP4Homo sapiens (human)
nucleosome assemblyHistone-binding protein RBBP4Homo sapiens (human)
DNA replication-dependent chromatin assemblyHistone-binding protein RBBP4Homo sapiens (human)
chromatin remodelingHistone-binding protein RBBP4Homo sapiens (human)
regulation of DNA-templated transcriptionHistone-binding protein RBBP4Homo sapiens (human)
brain developmentHistone-binding protein RBBP4Homo sapiens (human)
negative regulation of cell population proliferationHistone-binding protein RBBP4Homo sapiens (human)
negative regulation of cell migrationHistone-binding protein RBBP4Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayHistone-binding protein RBBP4Homo sapiens (human)
regulation of cell fate specificationHistone-binding protein RBBP4Homo sapiens (human)
negative regulation of DNA-templated transcriptionHistone-binding protein RBBP4Homo sapiens (human)
positive regulation of DNA-templated transcriptionHistone-binding protein RBBP4Homo sapiens (human)
negative regulation of stem cell population maintenanceHistone-binding protein RBBP4Homo sapiens (human)
positive regulation of stem cell population maintenanceHistone-binding protein RBBP4Homo sapiens (human)
regulation of stem cell differentiationHistone-binding protein RBBP4Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIPolycomb protein SUZ12Homo sapiens (human)
cell population proliferationPolycomb protein SUZ12Homo sapiens (human)
positive regulation of cell population proliferationPolycomb protein SUZ12Homo sapiens (human)
negative regulation of cell differentiationPolycomb protein SUZ12Homo sapiens (human)
oligodendrocyte differentiationPolycomb protein SUZ12Homo sapiens (human)
random inactivation of X chromosomePolycomb protein SUZ12Homo sapiens (human)
facultative heterochromatin formationPolycomb protein SUZ12Homo sapiens (human)
G1/S transition of mitotic cell cycleHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
chromatin organizationHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
regulation of DNA-templated transcriptionHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
positive regulation of cell population proliferationHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
positive regulation of epithelial to mesenchymal transitionHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
regulation of gliogenesisHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
skeletal muscle satellite cell maintenance involved in skeletal muscle regenerationHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
cardiac muscle hypertrophy in response to stressHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
cerebellar cortex developmentHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
hippocampus developmentHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
B cell differentiationHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
keratinocyte differentiationHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
positive regulation of cell migrationHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
regulatory ncRNA-mediated heterochromatin formationHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
subtelomeric heterochromatin formationHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
methylationHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
response to estradiolHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
negative regulation of transcription elongation by RNA polymerase IIHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
cellular response to trichostatin AHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
protein modification processHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
hepatocyte homeostasisHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
regulation of circadian rhythmHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
positive regulation of MAP kinase activityHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
positive regulation of GTPase activityHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
negative regulation of keratinocyte differentiationHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
negative regulation of gene expression, epigeneticHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
negative regulation of DNA-templated transcriptionHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
negative regulation of retinoic acid receptor signaling pathwayHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
rhythmic processHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
stem cell differentiationHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
negative regulation of striated muscle cell differentiationHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
synaptic transmission, GABAergicHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
cellular response to hydrogen peroxideHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
G1 to G0 transitionHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
protein localization to chromatinHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
positive regulation of protein serine/threonine kinase activityHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
regulation of kidney developmentHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
liver regenerationHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
facultative heterochromatin formationHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
positive regulation of dendrite developmentHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
negative regulation of cytokine production involved in inflammatory responseHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
positive regulation of cell cycle G1/S phase transitionHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
response to tetrachloromethaneHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
negative regulation of G1/S transition of mitotic cell cycleHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
negative regulation of stem cell differentiationHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
heterochromatin formationHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone-binding protein RBBP7Homo sapiens (human)
DNA replicationHistone-binding protein RBBP7Homo sapiens (human)
chromatin remodelingHistone-binding protein RBBP7Homo sapiens (human)
regulation of DNA-templated transcriptionHistone-binding protein RBBP7Homo sapiens (human)
brain developmentHistone-binding protein RBBP7Homo sapiens (human)
negative regulation of cell growthHistone-binding protein RBBP7Homo sapiens (human)
negative regulation of cell migrationHistone-binding protein RBBP7Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayHistone-binding protein RBBP7Homo sapiens (human)
regulation of cell fate specificationHistone-binding protein RBBP7Homo sapiens (human)
negative regulation of DNA-templated transcriptionHistone-binding protein RBBP7Homo sapiens (human)
positive regulation of DNA-templated transcriptionHistone-binding protein RBBP7Homo sapiens (human)
response to steroid hormoneHistone-binding protein RBBP7Homo sapiens (human)
cellular heat acclimationHistone-binding protein RBBP7Homo sapiens (human)
negative regulation of stem cell population maintenanceHistone-binding protein RBBP7Homo sapiens (human)
positive regulation of stem cell population maintenanceHistone-binding protein RBBP7Homo sapiens (human)
regulation of stem cell differentiationHistone-binding protein RBBP7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (26)

Processvia Protein(s)Taxonomy
transcription corepressor bindingPolycomb protein EEDHomo sapiens (human)
protein bindingPolycomb protein EEDHomo sapiens (human)
enzyme activator activityPolycomb protein EEDHomo sapiens (human)
histone methyltransferase activityPolycomb protein EEDHomo sapiens (human)
identical protein bindingPolycomb protein EEDHomo sapiens (human)
nucleosome bindingPolycomb protein EEDHomo sapiens (human)
ATP-dependent activity, acting on DNAHistone-binding protein RBBP4Homo sapiens (human)
nucleosomal DNA bindingHistone-binding protein RBBP4Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingHistone-binding protein RBBP4Homo sapiens (human)
protein bindingHistone-binding protein RBBP4Homo sapiens (human)
histone bindingHistone-binding protein RBBP4Homo sapiens (human)
histone deacetylase bindingHistone-binding protein RBBP4Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingPolycomb protein SUZ12Homo sapiens (human)
transcription corepressor bindingPolycomb protein SUZ12Homo sapiens (human)
protein bindingPolycomb protein SUZ12Homo sapiens (human)
enzyme activator activityPolycomb protein SUZ12Homo sapiens (human)
methylated histone bindingPolycomb protein SUZ12Homo sapiens (human)
histone methyltransferase activityPolycomb protein SUZ12Homo sapiens (human)
metal ion bindingPolycomb protein SUZ12Homo sapiens (human)
lncRNA bindingPolycomb protein SUZ12Homo sapiens (human)
promoter-specific chromatin bindingPolycomb protein SUZ12Homo sapiens (human)
chromatin DNA bindingPolycomb protein SUZ12Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
RNA polymerase II core promoter sequence-specific DNA bindingHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
transcription corepressor bindingHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
chromatin bindingHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
transcription corepressor activityHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
protein bindingHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
protein-lysine N-methyltransferase activityHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
chromatin DNA bindingHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
histone methyltransferase activityHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
ribonucleoprotein complex bindingHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
histone H3K27 methyltransferase activityHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
primary miRNA bindingHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
lncRNA bindingHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
histone H3 methyltransferase activityHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
histone H3K27 trimethyltransferase activityHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
promoter-specific chromatin bindingHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
RNA bindingHistone-binding protein RBBP7Homo sapiens (human)
protein bindingHistone-binding protein RBBP7Homo sapiens (human)
histone bindingHistone-binding protein RBBP7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (23)

Processvia Protein(s)Taxonomy
nucleusPolycomb protein EEDHomo sapiens (human)
nucleoplasmPolycomb protein EEDHomo sapiens (human)
chromosomePolycomb protein EEDHomo sapiens (human)
cytosolPolycomb protein EEDHomo sapiens (human)
ESC/E(Z) complexPolycomb protein EEDHomo sapiens (human)
chromosome, telomeric regionHistone-binding protein RBBP4Homo sapiens (human)
chromatinHistone-binding protein RBBP4Homo sapiens (human)
nucleusHistone-binding protein RBBP4Homo sapiens (human)
nucleoplasmHistone-binding protein RBBP4Homo sapiens (human)
cytosolHistone-binding protein RBBP4Homo sapiens (human)
NuRD complexHistone-binding protein RBBP4Homo sapiens (human)
NURF complexHistone-binding protein RBBP4Homo sapiens (human)
CAF-1 complexHistone-binding protein RBBP4Homo sapiens (human)
Sin3-type complexHistone-binding protein RBBP4Homo sapiens (human)
ATPase complexHistone-binding protein RBBP4Homo sapiens (human)
histone deacetylase complexHistone-binding protein RBBP4Homo sapiens (human)
protein-containing complexHistone-binding protein RBBP4Homo sapiens (human)
ESC/E(Z) complexHistone-binding protein RBBP4Homo sapiens (human)
nucleusHistone-binding protein RBBP4Homo sapiens (human)
nucleusPolycomb protein SUZ12Homo sapiens (human)
nucleoplasmPolycomb protein SUZ12Homo sapiens (human)
nucleolusPolycomb protein SUZ12Homo sapiens (human)
nuclear bodyPolycomb protein SUZ12Homo sapiens (human)
sex chromatinPolycomb protein SUZ12Homo sapiens (human)
chromatin silencing complexPolycomb protein SUZ12Homo sapiens (human)
ESC/E(Z) complexPolycomb protein SUZ12Homo sapiens (human)
ribonucleoprotein complexPolycomb protein SUZ12Homo sapiens (human)
RSC-type complexPolycomb protein SUZ12Homo sapiens (human)
nucleusPolycomb protein SUZ12Homo sapiens (human)
chromosomeHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
chromosome, telomeric regionHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
nucleusHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
nucleoplasmHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
pronucleusHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
synapseHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
chromatinHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
chromatin silencing complexHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
pericentric heterochromatinHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
ESC/E(Z) complexHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
nucleusHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
chromosome, telomeric regionHistone-binding protein RBBP7Homo sapiens (human)
nucleusHistone-binding protein RBBP7Homo sapiens (human)
nucleoplasmHistone-binding protein RBBP7Homo sapiens (human)
cytosolHistone-binding protein RBBP7Homo sapiens (human)
NuRD complexHistone-binding protein RBBP7Homo sapiens (human)
NURF complexHistone-binding protein RBBP7Homo sapiens (human)
Sin3-type complexHistone-binding protein RBBP7Homo sapiens (human)
ATPase complexHistone-binding protein RBBP7Homo sapiens (human)
histone deacetylase complexHistone-binding protein RBBP7Homo sapiens (human)
ESC/E(Z) complexHistone-binding protein RBBP7Homo sapiens (human)
nucleusHistone-binding protein RBBP7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (33)

Assay IDTitleYearJournalArticle
AID1151972Cytotoxicity against human Pfeiffer cells expressing EZH2 A667G mutant assessed as growth inhibition after 72 hrs by WST-1 assay2014Bioorganic & medicinal chemistry letters, Jun-01, Volume: 24, Issue:11
Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors.
AID1151968Inhibition of EZH2 histone methyltransferase activity in EZH2/SUZ12/EED protein complex (unknown origin) using histone H3 peptide/S-adenosylmethionine as substrate after 2 hrs by TR-FRET assay2014Bioorganic & medicinal chemistry letters, Jun-01, Volume: 24, Issue:11
Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors.
AID1151997Inhibition of EZH2 histone methyltransferase in human pfeiffer cells assessed as inhibition of H3K27me3 methylation at 3 uM after 72 hrs by ELISA2014Bioorganic & medicinal chemistry letters, Jun-01, Volume: 24, Issue:11
Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors.
AID1151991Induction of apoptosis in human Pfeiffer cells assessed as DNA content at 1 to 5 uM after 72 hrs by DAPI staining-based analysis2014Bioorganic & medicinal chemistry letters, Jun-01, Volume: 24, Issue:11
Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors.
AID1151986Cell cycle arrest in human Pfeiffer cells assessed as accumulation at S phase at 2.5 uM after 72 hrs (Rvb = 21%)2014Bioorganic & medicinal chemistry letters, Jun-01, Volume: 24, Issue:11
Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors.
AID1151996Inhibition of EZH2 histone methyltransferase in human pfeiffer cells assessed as inhibition of H3K27me3 methylation after 48 hrs by Western blotting analysis2014Bioorganic & medicinal chemistry letters, Jun-01, Volume: 24, Issue:11
Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors.
AID1151977Cytotoxicity against human U87MG cells assessed as growth inhibition after 72 hrs by WST-1 assay2014Bioorganic & medicinal chemistry letters, Jun-01, Volume: 24, Issue:11
Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors.
AID1151992Induction of apoptosis in human Pfeiffer cells assessed as increase in cleaved caspase-3 level at 1 to 3 uM after 72 hrs by Western blotting analysis2014Bioorganic & medicinal chemistry letters, Jun-01, Volume: 24, Issue:11
Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors.
AID1151975Cytotoxicity against human PC3 cells assessed as growth inhibition after 72 hrs by WST-1 assay2014Bioorganic & medicinal chemistry letters, Jun-01, Volume: 24, Issue:11
Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors.
AID1151979Cell cycle arrest in human Pfeiffer cells assessed as accumulation at sub-G1 phase at 1 uM after 72 hrs (Rvb = 9%)2014Bioorganic & medicinal chemistry letters, Jun-01, Volume: 24, Issue:11
Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors.
AID1151989Cell cycle arrest in human Pfeiffer cells assessed as accumulation at G2/M phase at 2.5 uM after 72 hrs (Rvb = 10%)2014Bioorganic & medicinal chemistry letters, Jun-01, Volume: 24, Issue:11
Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors.
AID1151969Competitive inhibition of EZH2 histone methyltransferase activity in EZH2/SUZ12/EED/RbAp46/48 (unknown origin) using histone H3 peptide/varying concentration of S-adenosylmethionine as substrate after 2 hrs by Lineweaver-Burk plot analysis2014Bioorganic & medicinal chemistry letters, Jun-01, Volume: 24, Issue:11
Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors.
AID1151982Cell cycle arrest in human Pfeiffer cells assessed as accumulation at G1 phase at 1 uM after 72 hrs (Rvb = 59%)2014Bioorganic & medicinal chemistry letters, Jun-01, Volume: 24, Issue:11
Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors.
AID1151973Cytotoxicity against human U2932 cells assessed as growth inhibition after 72 hrs by WST-1 assay2014Bioorganic & medicinal chemistry letters, Jun-01, Volume: 24, Issue:11
Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors.
AID1151970Mixed-type inhibition of EZH2 histone methyltransferase activity in EZH2/SUZ12/EED/RbAp46/48 protein complex (unknown origin) using histone H3 peptide/varying concentration of S-adenosylmethionine as substrate after 2 hrs by Lineweaver-Burk plot analysis2014Bioorganic & medicinal chemistry letters, Jun-01, Volume: 24, Issue:11
Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors.
AID1151983Cell cycle arrest in human Pfeiffer cells assessed as accumulation at G1 phase at 2.5 uM after 72 hrs (Rvb = 59%)2014Bioorganic & medicinal chemistry letters, Jun-01, Volume: 24, Issue:11
Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors.
AID1151981Cell cycle arrest in human Pfeiffer cells assessed as accumulation at sub-G1 phase at 5 uM after 72 hrs (Rvb = 9%)2014Bioorganic & medicinal chemistry letters, Jun-01, Volume: 24, Issue:11
Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors.
AID1151974Cytotoxicity against human Daudi cells assessed as growth inhibition after 72 hrs by WST-1 assay2014Bioorganic & medicinal chemistry letters, Jun-01, Volume: 24, Issue:11
Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors.
AID1151993Induction of apoptosis in human Pfeiffer cells assessed as increase in cleaved caspase-7 level at 1 to 3 uM after 72 hrs by Western blotting analysis2014Bioorganic & medicinal chemistry letters, Jun-01, Volume: 24, Issue:11
Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors.
AID1151976Cytotoxicity against human T98G cells assessed as growth inhibition after 72 hrs by WST-1 assay2014Bioorganic & medicinal chemistry letters, Jun-01, Volume: 24, Issue:11
Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors.
AID1151990Cell cycle arrest in human Pfeiffer cells assessed as accumulation at G2/M phase at 5 uM after 72 hrs (Rvb = 10%)2014Bioorganic & medicinal chemistry letters, Jun-01, Volume: 24, Issue:11
Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors.
AID1151980Cell cycle arrest in human Pfeiffer cells assessed as accumulation at sub-G1 phase at 2.5 uM after 72 hrs (Rvb = 9%)2014Bioorganic & medicinal chemistry letters, Jun-01, Volume: 24, Issue:11
Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors.
AID1151987Cell cycle arrest in human Pfeiffer cells assessed as accumulation at S phase at 5 uM after 72 hrs (Rvb = 21%)2014Bioorganic & medicinal chemistry letters, Jun-01, Volume: 24, Issue:11
Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors.
AID1882367Inhibition of EZH2 (unknown origin)2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Fascinating Transformation of SAM-Competitive Protein Methyltransferase Inhibitors from Nucleoside Analogues to Non-Nucleoside Analogues.
AID1151994Induction of apoptosis in human Pfeiffer cells assessed as increase in cleaved PARP level at 1 to 3 uM after 72 hrs by Western blotting analysis2014Bioorganic & medicinal chemistry letters, Jun-01, Volume: 24, Issue:11
Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors.
AID1882373Binding affinity to EZH2 (unknown origin) assessed as inhibition constant2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Fascinating Transformation of SAM-Competitive Protein Methyltransferase Inhibitors from Nucleoside Analogues to Non-Nucleoside Analogues.
AID1151985Cell cycle arrest in human Pfeiffer cells assessed as accumulation at S phase at 1 uM after 72 hrs (Rvb = 21%)2014Bioorganic & medicinal chemistry letters, Jun-01, Volume: 24, Issue:11
Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors.
AID1151984Cell cycle arrest in human Pfeiffer cells assessed as accumulation at G1 phase at 5 uM after 72 hrs (Rvb = 59%)2014Bioorganic & medicinal chemistry letters, Jun-01, Volume: 24, Issue:11
Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors.
AID1151978Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by WST-1 assay2014Bioorganic & medicinal chemistry letters, Jun-01, Volume: 24, Issue:11
Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors.
AID1151988Cell cycle arrest in human Pfeiffer cells assessed as accumulation at G2/M phase at 1 uM after 72 hrs (Rvb = 10%)2014Bioorganic & medicinal chemistry letters, Jun-01, Volume: 24, Issue:11
Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors.
AID1151971Inhibition of EZH2 histone methyltransferase A667G mutant in EZH2/SUZ12/EED/RbAp46/48 protein complex (unknown origin) using histone H3 peptide/S-adenosylmethionine as substrate after 2 hrs by Lineweaver-Burk plot analysis2014Bioorganic & medicinal chemistry letters, Jun-01, Volume: 24, Issue:11
Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors.
AID1151995Inhibition of EZH2 histone methyltransferase in human pfeiffer cells assessed as inhibition of H3K27me3 methylation at 1 to 3 uM after 72 hrs by ELISA2014Bioorganic & medicinal chemistry letters, Jun-01, Volume: 24, Issue:11
Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors.
AID1151998Inhibition of EZH2 histone methyltransferase in human pfeiffer cells assessed as inhibition of H3K27me3 methylation at 3 uM after 48 hrs by Western blotting analysis2014Bioorganic & medicinal chemistry letters, Jun-01, Volume: 24, Issue:11
Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (4)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (25.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (50.00)24.3611
2020's1 (25.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.72

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.72 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.72)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
pentamidine
Pentamidine: Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of PNEUMOCYSTIS pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects.. pentamidine : A diether consisting of pentane-1,5-diol in which both hydroxyl hydrogens have been replaced by 4-amidinophenyl groups. A trypanocidal drug that is used for treatment of cutaneous leishmaniasis and Chagas disease.		2.4110aromatic ether;
carboxamidine;
diether		anti-inflammatory agent;
antifungal agent;
calmodulin antagonist;
chemokine receptor 5 antagonist;
EC 2.3.1.48 (histone acetyltransferase) inhibitor;
NMDA receptor antagonist;
S100 calcium-binding protein B inhibitor;
trypanocidal drug;
xenobiotic
hexamidine
hexamidine : A polyether that is the bis(4-guanidinophenyl) ether of hexane-1,6-diol.		2.4110aromatic ether;
guanidines;
polyether		antimicrobial agent;
antiseptic drug
1,7-phenanthroline
[no description available]		1.9610phenanthroline
tanshinone
tanshinone: from root of Salvia miltiorrhiza Bunge; RN given refers to tanshinone I; cardioprotective agent and neuroprotective agent		2.110abietane diterpenoidanticoronaviral agent
tanshinone ii a
tashinone IIA: a cardiovascular agent with antineoplastic activity; isolated from Salvia miltiorrhiza; structure in first source		2.110abietane diterpenoid
epz005687
EPZ005687: inhibits EZH2 protein; structure in first source		2.4110indazoles
gsk-2816126
GSK-2816126: inhibits EZH2 methyltransferase; structure in first source		2.5820piperazines;
pyridines
gsk343
GSK343: an EZH2 methyltransferase inhibitor. GSK343 : A member of the class of indazoles that is 1-isopropyl-1H-indazole-4-carboxamide in which the nitrogen of the carboxamide group is substituted by a (6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl group and in which the indazole ring is substituted at position 6 by a 2-(4-methylpiperazin-1-yl)pyridin-4-yl group. A highly potent and selective EZH2 inhibitor (IC50 = 4 nM).		2.4110aminopyridine;
indazoles;
N-alkylpiperazine;
N-arylpiperazine;
pyridone;
secondary carboxamide		antineoplastic agent;
apoptosis inducer;
EC 2.1.1.43 (enhancer of zeste homolog 2) inhibitor
ConditionIndicatedRelationship StrengthStudiesTrials
Atherogenesis
[description not available]		02.1710
Atherosclerosis
A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA.		02.1710